Anzeige
Mehr »
Login
Samstag, 25.01.2025 Börsentäglich über 12.000 News von 683 internationalen Medien
Hinter dem nuklearen Ansturm im Silicon Valley: Eine strategische Chance entsteht
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40SU2 | ISIN: US0209521071 | Ticker-Symbol:
NASDAQ
24.01.25
22:00 Uhr
1,760 US-Dollar
-0,080
-4,35 %
Branche
Software
Aktienmarkt
Sonstige
1-Jahres-Chart
ALPHA MODUS HOLDINGS INC Chart 1 Jahr
5-Tage-Chart
ALPHA MODUS HOLDINGS INC 5-Tage-Chart
GlobeNewswire (Europe)
111 Leser
Artikel bewerten:
(0)

Alpha Modus Corp.: Alpha Modus Appoints Accomplished Executive Thomas Gallagher as Chief Revenue Officer to Drive Growth and Maximize Shareholder Value

Finanznachrichten News

CORNELIUS, N.C., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Alpha Modus Holdings, Inc. (Nasdaq: AMOD) ("Alpha Modus" or the "Company"), is pleased to announce the appointment of Thomas Gallagher as Chief Revenue Officer (CRO) of the Company. In this role, Mr. Gallagher will oversee global revenue generation strategies, scaling operations, and aligning the Company's sales, marketing, and business development efforts to accelerate growth and deliver robust shareholder returns.

Mr. Gallagher brings over two decades of proven leadership in driving revenue growth, strategic expansion, and operational excellence in competitive markets. Most recently, Mr. Gallagher served as Senior Vice President of Services and Solutions at Zones, where he spearheaded transformative strategies that significantly enhanced sales and operational efficiency. Prior to that, he held pivotal roles including Chief Sales Officer of Cloud Infrastructure Services at Capgemini North America and Vice President of Sales for North and South American Industries at DXC. His extensive experience also includes senior sales positions at IBM, HP/EDS, and AT&T.

"Thomas Gallagher is an outstanding addition to the Alpha Modus leadership team," said William Alessi, CEO. "His exceptional track record of delivering measurable results and building high-performing teams, coupled with his cross-industry expertise, will be instrumental as we target scaling our business and capitalizing on growth opportunities."

Throughout his career, Mr. Gallagher has demonstrated a deep understanding of market dynamics and a commitment to fostering strong relationships with customers, partners, and stakeholders. At Alpha Modus, he will lead initiatives in sales, operations, marketing, pricing strategies, partnerships, and revenue management, positioning the company for sustainable growth and enhanced profitability.

"I am thrilled to join Alpha Modus at such a pivotal moment in its journey," said Mr. Gallagher. "The Company has built a strong foundation as an AI innovator and IP owner and is well-positioned for continued success. I look forward to working with the talented team to drive innovation, unlock new revenue opportunities, and create lasting value for our shareholders."

This strategic appointment underscores Alpha Modus' commitment to advancing its growth strategy and delivering long-term value to its stakeholders. As Mr. Gallagher steps into this critical leadership role, Alpha Modus is squarely focused on achieving ambitious revenue targets and establishing its position as an industry leader.

About Thomas Gallagher

Mr. Gallagher is a seasoned technology executive with a robust background in sales and go-to-market leadership. A graduate of the United States Naval Academy with a degree in Systems Engineering, he served as a Captain in the United States Marine Corps for five years. He currently resides in New Jersey.

About Alpha Modus

Alpha Modus engages in creating, developing and licensing data-driven technologies to enhance consumers' in-store experience at the point of decision. Alpha Modus's patent portfolio positions the Company as a leader in the evolving landscape of AI retail technology. With the ability to transform how consumers interact with brands at the point of sale, Alpha Modus is strategically positioned to capitalize on the increasing demand for AI-driven solutions that deliver measurable ROI for retailers and brands.

For additional information, please visit alphamodus.com.

Forward-Looking Statements

This press release includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Alpha Modus' actual results may differ from their expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements, but are not the exclusive means of identifying these statements. These forward-looking statements include, without limitation, Alpha Modus' expectations with respect to future performance.

Alpha Modus cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Alpha Modus does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.

Contacts:

Alpha Modus Holdings, Inc.

Investor Relations

ir@alphamodus.com

+1(704)252-5050


© 2025 GlobeNewswire (Europe)
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.